Celerion Revenue and Competitors

Lincoln, NE USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Celerion's estimated annual revenue is currently $323.9M per year.(i)
  • Celerion's estimated revenue per employee is $321,600

Employee Data

  • Celerion has 1007 Employees.(i)
  • Celerion grew their employee count by 3% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$11.3M5624%N/AN/A
#2
$323.9M10073%N/AN/A
#3
$76.6M3819%N/AN/A
#4
$5.8M29-15%N/AN/A
#5
$9.6M480%N/AN/A
#6
$14.9M749%N/AN/A
Add Company

Celerion is the premier provider of innovative early stage clinical research solutions. From facilities strategically located around the world, advanced scientific and technological expertise is applied to clinical research (over 730 beds in Phases 0, I and IIa, NDA-enabling clinical pharmacology, ADME), clinical pharmacology sciences, bioanalytical services (discovery through late stage), and drug development services. Celerion has a full spectrum of resources to meet the needs of the pharmaceutical, biotechnology and generic industries for Phase 0 through IIa proof-of-concept studies.

keywords:N/A

N/A

Total Funding

1007

Number of Employees

$323.9M

Revenue (est)

3%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Celerion's People

NameTitleEmail/Phone
1
CFOReveal Email/Phone
2
VP, Data Management and BiometricsReveal Email/Phone
3
VP, Drug Development ServicesReveal Email/Phone
4
Archives AssistantReveal Email/Phone
5
Reference Standards ScientistReveal Email/Phone
6
Senior Director, Lincoln Clinical SiteReveal Email/Phone
7
Director, Proposal and Financial Management, Global Project ManagementReveal Email/Phone
8
MEDICAL DIRECTOR AND PRINCIPAL INVESTIGATORReveal Email/Phone
9
Revenue Recognition & Forecasting SpecialistReveal Email/Phone
10
Bioanalytical Principal InvestigatorReveal Email/Phone

Celerion News

2022-04-20 - Suzuki PH teases 2022 Celerio - Auto News

This is your first glimpse of the all-new Suzuki Celerio for PH. Suzuki Today - 9:48 AM.

2022-04-17 - Non-Alcoholic Steatohepatitis Biomarkers Market Size And ...

BioPredictive, Cisbio, Celerion, Echosens, NGM Biopharmaceuticals, Gilead, AstraZeneca, Novartis AG, Novo Nordisk A/S, Pfizer, Inc.

2022-03-30 - Celerion Announces Investment in ADME Suite of Services

Celerion, a global leader in early clinical research services, offers a unique combination of medical expertise, clinical operations experience,...

2021-06-01 - Celerion Receives CRO Leadership Award for 6th Consecutive Year USA - English France - Français España - español Deutschland - Deutsch

LINCOLN, Neb., June 1, 2021 /PRNewswire/ -- Celerion is pleased to announce that they are the recipient of the 2021 Life Science Leader annual CRO Leadership Awards in all five award categories. This is the sixth consecutive year that Celerion has so been honored. Well respected within the ph ...

2014-10-29 - Celerion Announces Recapitalization through Investment by MTS Health Investors

Celerion, a Lincoln, NE-based provider of clinical study solutions to pharmaceutical and biotechnology clients conducting early clinical research, has announced the successful recapitalization of its business through investment by MTS Health Investors, LLC, a New York-based healthcare private eq ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$355.2M10448%N/A
#2
$75M1138N/AN/A
#3
$334.6M11388%N/A
#4
$455.5M12059%N/A
#5
$460.4M12186%N/A